Upon confirmation from other independent research, the undersigned also requests the Commissioner of Food and Drugs issue a public health alert as to breast-feeding or pregnancy to avoid possible genotoxic effects and advice as to removal to avoid potential or worsening health consequences. It is further requested that all remaining inventories of SGFBIs in the United States be destroyed in order to protect the health of women and our future generations.
In support of the above requests, I submit the foIlowing: 1. Published peer-reviewed research Release of Low Molecular Weight Silicones and Platinum from Silicone Breast Implants (1997) by Baylor College of Medicine documents the ability of new equipment (GC-AED, GC/MS, ICP-MS) to detect silicones in the nanogram range and platinum in the parts per trillion range. This research also studied the rates at which low molecular (LM) silicones and platinum leak through the intact implant outer shell into surrounding media under a variety of conditions. Leakage was greatest when the surrounding medium was lipid-rich and, potentially, could lead to significant accumulation within lipid rich tissues (breast tissue, brain tissue, myelin, etc.) Previous research Measurement of Platinum in Biomedical Silicones bv ICP-MS (1995) and subsequent research Platinum concentration in urban road dust and soiL and in blood and urine in the United Kinpdom (1998), both used ICP-MS to measure platinum release from either silicone gel-filled implants or concentration in body fluids. The 1995 research by El-Jarnmal and Templeton found platinum was present at approximately 4.5 micrograms per gram (-1) in a silicone breast implant but was absent from medical grade silicone oil, indicating that platinum used as a catalyst in polymerization was not removed from implanted devices. 2. New research soon to be submitted for publication by Ernest Lykissa, Ph.D., using ICP-MS to measure the amount of platinum release and ion chromatography to speciate the platinum release, has shown that of the eight SGFBI's tested all eight had significant release of pIatinum. Most of which was in a toxic hypersensitizing reactive valence (see attached estimates the amounts of platinum salts present in two 250 cc silicone gel implants _. demonstrate an in vivo platinum salts exposure to platinum in women with silicone gel implants 1000 x greater then the occupationally allowed limit. The OSHA permissible airborne exposure limit is 0.002 mg Pt/m3 for soluble platinum salts in industrial workers (OSHA 1981). Dr. Wabeke states "How much ionized platinum remains in vivo is debatable, but any analytically-detectable amount, in my view, given the high toxicity and biological reactivity of soluble ionized platinum, is too much". Wabeke sites the research by Agnew et al., Neurooathological Effects of Intracerebral Platinum Salt I&&ions which studied the effects of multiple injections of two platinum salts (potassium chloroplatinate and chloroplatinic acid) on cat brain He concludes the amounts of platinum used in this research are within the same order of magnitude as those detected in the silicone implants. Furthermore, Schuppe et a1 T-Cell-Deuendent Pouital Lvmnh Node Reactions to Platinum Comnounds in Mice (1992) demonstrated immunogenicity after injections of hexachloroplatinate into mice. As in the Agnew et al research, the amounts of platinum used are in the same range as amounts of platinum in the silitione implant materials. Wabeke states "Clearly, breast implants weigh more than one gram, so the total amount of implanted platinum in humans exceeds treated-mice amounts." 5. The research of Potter, et al., Induction of Plasmacvtomas with Silicone Gel iu Genetically Susceptible Strains of Mice (1994) establishes that platinic chloride is a water-soluble form of the metal that is used as the preferred catalyst in medical silicone gels and elastomers, Their work further establishes that any soluble platinum leaching from an implant would be expected to distribute in the circulation as a chloroplatinate. Dow Corning research on nipples for baby bottles determined that pIatinum leached out into a water solution as well as the other solutions used including ethanol in water, acatic acid and olive oil. 6. The toxicity and hypersensitivity of platinum salts is already known and well documented.
The following statements can be found in the book Platinum published by the World Health Organization and the International Programme on Chemical Safety (1991): "During the course of a reproduction study, behavioral effects were observed in the offspring of mice treated with sodium hexachIoroplatinate.. .The symptoms typical of platinum salt sensitization (Brooks 1990) (3) 149-154 (b) The Institute of Medicine (IOM) report states "Consistent with animal toxicology studies noted earlier, it appears that NK cells in humans might be affected by exposure to silicone gel, since removal of silicone breast implants was followed by an increase in NK-cell function in 50% of women studied by CampbelI. This research is supported by the, as yet, unpublished data (see Attachment 3) submitted by Patricia D. Salvato, MD (Sept. 2000) "Silicone Breast Implants and Natural Killer Cell Numbers". Of 633 breast implanted patients evaluated by Dr. Salvato, the range of natural killer cell counts was Tom 8 to 256, with an average of 110. Of 136 healthy controls, the range was from 320-550, with an average of 410. Dr. Salvato states "From this data it can be postulated that silicone has a direct and toxic effect on natural killer cell numbers in patients with silicone breast disease. It has been reported in the medical literature that natural killer cell activity may somehow impinge on the central nervous system Natural killer cells are capable of crossing the blood brain barrier and are present in the brain and certain pathologic states. It has also been reported that natural killer cells express receptors for neuropeptides and hormones. It has also been shown that products of activated natural killer cells are damaging to the neurons. Some of the activated natural killer cells infiltrating normal tissue might cause local damage that would impinge on cells of the central nervous systems of patients, thus manifesting as a cause of neuro-endocrine abnormalities. This research lends more evidence to the growing medical literature supportive of silicone's toxic effects on the immune system, central nervous system, and peripheral nervous system." 13. The argument could be made that there are no published controlled epidemiological studies demonstrating a risk of allergy (hypersensitivity) related to breast implants, only because no study has actually examined and tested breast-implanted patients. Compelling new research by Brawer (2000) demonstrating improvement of systemic phenomena and disease amelioration following explantation, provides supportive evidence for the existence of a novel illness triggered by silicone gel-filled devices. The argument that a large controlled epidemiological study documenting a health risk to platinum salts is needed before gel-filled breast implants can be removed from the market is not applicable here because of the enormous potency of platinum salts. To quote Drs. Niezborala and Gamer in regard to industrial contact "At no stage should a worker be able to come into contact with a solution or a solid containing these particular complex platinum salts". In other words, there is no "safe" level of platinum salts in implanted devices. Furthermore, platinum salts are considered so toxic that the consensus opinion in Occupational Medicine is that platinum allergy exists in a worker presenting with classic allergy symptoms (who is exposed to platinum salts) until proven otherwise according to Michael Harbut, MD.
From 1985 until January 2000, FDA has received 127,770 adverse reaction reports for SGFBI's (adverse events include death, life-threatening injury or illness, hospitalization, disability, birth abnormality, or medical intervention to prevent permanent impairment or damage). To allow this toxic defective class III device to remain on the market is egregious conduct on the part of the manufacturers, who are required by law to prove breast implants to be safe, and the FDA, whose mission is to protect the consumer and their unborn children. The Nuremberg Code states a person should give consent and exercise free power of choice without the intervention of any element of force, fraud. deceit. duress, over-reaching, or other ulterior form of constraint or coercion. They also should have sufficient knowledge and comprehension of the elements of the subj@ matter involved to make an understanding and enlightened decision. Furthermore during the course of the experiment, the scientist in charge must be prepared to terminate the experiment at any stage, if he has probable cause to believe, in the exercise of the good faith, superior skill, and careful judgment required of him, that a continuation of the experiment is likely to result in injury, disability or death to the experimental subject. While women can remove their implants, there is no way for them to end the experiment and remove the platinum-cyclosiloxane complexes when it spreads to all parts of their bodies. Safety must matter.
ENVIRONMENTAL IMPACT -I request a waiver on the environmental assessment under Sec. 25.3 1. I believe there will be a positive environmental impact when SGFBI's are removed from the market because there will be less toxic waste to dispose of when implants are removed. I believe women and their children will experience less toxic poisoning and environmental injury when SGFBI's are no longer placed in their bodies or when silicone, silica, or its components (toxic and hypersensitizing platinum) are passed in the placenta or in breast milk. \ ECONOMIC IMPACT -Revoking the implantation of SGFBI's will help balance the budget and reduce the deficit. Less money will have to be paid out when former hard working productive women implanted with SGFBI's become disabled, can no longer work, lose their insurance, or can no longer care for themselves and their families (refer to the U.S. Justice Dept. claim in the Dow Bankruptcy). This should have a favorable economic impact on the individual considering SGFBI's in long term health care savings. Just because there is insufficient data does not mean that a new disease as a result of exposure to toxic and hypersensitizing chemicals does not exist, it simply means that the long-term studies have not been done. We do not know the frequency of complications or the severity of disease, because a national registry was never mandated. Because of the latency period of systemic symptoms to appear, doctors and women have been slow to recognize their disease and that of their children born after implantation, may be related to their implants. The FDA's Scleroderma Court Study and the NCI's Study of 13,500 Breast Implanted Women should soon document that something has gone tragically wrong. Furthermore the FDA's own research as published in the Annual Report 1998 Office of Science and Technology documents statistically significant elevated autoantibodies to collagen type I, collagen type II and anti-DNA were detected in serum of patients with Connective Tissue Disease (CTD), CTD + silicone implants, and silicone implants without CTD.
A possible negative impact to the economy might be a loss of income for the Plastic Surgeons who have come to depend on the easy money generated by breast implants, the repeat surgeries they require, and the high cost of explantation when rupture or severe gel bleed occur. However, with the availability of saline-fdled impiants and other reconstruction options, this should not be an undue hardship. When choice may damage a woman's health and that of her unborn children, they must be protected.
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